OvAge: an innovative, user-friendly digital methodology that quantifies ovarian reserve by integrating clinical, biochemical and 3D-sonographic data to help decision-making in all phases of woman life

Project Information

Ovage

Grant agreement ID: 781853

DOI

10.3030/781853

Project closed

EC signature date 31 July 2017

Start date 1 August 2017

End date 31 January 2018

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

OVAGE SRL
Italy

Periodic Reporting for period 1 - Ovage (OvAge: an innovative, user-friendly digital methodology that quantifies ovarian reserve by integratingclinical, biochemical and 3D-sonographic data to help decision-making in all phases of woman life)

Reporting period: 2017-08-01 to 2018-01-31

Summary of the context and overall objectives of the project

Infertility is becoming a public health issue in Europe. In the EU, infertility affects approximately 25 million citizens . In worildwide, it is estimated that one out of six people experience some form of infertility during their reproductive lifespan. Europe is characterized by low fertility, postponed childbearing, increase in childlessness among younger generations. OvAge s.r.l. is a business start-up born from one of the best cutting-edge research of the University Magna Graecia of Catanzaro. Its mission is to improve women quality of life by bringing to the international market medical devices for the solution of gynaecological diseases. OvAge s.r.l. is the owner of a pioneering medical device-software able in quantifying women ovarian reserve (OR) by integrating clinical, biochemical and 3D- ultrasonographic data. This instrument, called OvAge®, is already developed as a patented mathematical algorithm. OvAge® combines complementary evaluations to give as a result explicitly the ovarian age of every woman, a ready-to-use information that is going to revolutionize the relationship of women with themselves, their life and with the Specialists in the field of Gynaecology

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Ovage are planning to launch our product in the EU market initially through a web site. After SME instrument phase 1 conclusion, we aim to commercialize it in the rest of the EU market and in the rest of the world. Actually the Ovage's sell strategy contemplates a unique selling point into the web But, this is the best strategy?
The objective of the activities is to identify the best market strategy for Ovage.
The project plan was developed in 4 steps:
1. Recognize the characteristics of the market (Market segment identification)
2. Evaluate best process to keep a client's business (positioning strategy)
3. Define the Ovage’s commercial strategy
4. Investigate possible risks in our commercial strategy

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

At the end of the project Ovage knows:
- the right firm positioning
- the product and price strategy to be adopted
- the right price to transfer the rights of the patent

Ovage's logo